[3] Li H,Liu ZY,Wu N,et al. PARP inhibitor resistance:the underlying mechanisms and clinical implications[J]. Mol Cancer,2020,19(1):107. [4] Miller RE,Leary A,Scott CL,et al. ESMO recommendations on predictive biomarker testin...
《TherapeuticPotential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors》刊登于Frontiers in Oncology肿瘤学前沿杂志中,详述阐明了PARP抑制和免疫联合治疗在改善实体肿瘤患者预后方面的前景,总结早期研究成果并展望进行中的研究,下面就由小编来为大家解读一下这篇文章。
TOPACIO 研究旨在通过联合 PARP 抑制剂(尼拉帕利)和抗 PD-1(帕博利珠单抗)改善铂耐药/抵抗及 PARP 抑制剂单药疗效欠佳的卵巢癌患者的预后,扩大 PARP 抑制剂的适应症——既用于 BRCA 突变患者也用于 BRCA 基因野生型及铂耐药患者,这是这项研究的初衷。 结果显示,联合用药的 ORR 可达23%。亚组分析显示,对 BRCA ...
1#PARP inhibitor pick-me-up(来源:Nature Reviews Drug Discovery) 2#LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer(来源:默沙东官网) 3#New treatment combination...
PARP抑制剂可诱导的持续DNA损伤以增强免疫反应:通过增加肿瘤新生抗原的表达、增强程序性细胞死亡配体1(PD-L1)的表达、激活免疫通路(如cGAS-STING通路)来增强免疫反应,并将肿瘤免疫微环境调节为更具侵袭性的辅助T细胞1(TH1)状态。这些机制可以增强免疫系统并增强ICI的缓解速度和持久性,使得ICI和PARP抑制剂的组合成为...
PARP抑制剂可诱导的持续DNA损伤以增强免疫反应:通过增加肿瘤新生抗原的表达、增强程序性细胞死亡配体1(PD-L1)的表达、激活免疫通路(如cGAS-STING通路)来增强免疫反应,并将肿瘤免疫微环境调节为更具侵袭性的辅助T细胞1(TH1)状态。这些机制可以增强免疫系统并增强ICI的缓解速度和持久性,使得ICI和PARP抑制剂的组合成为...
Combination of PARP inhibitor and PD-1 binding antagonistThe present invention relates to a method of treating cancer, the step-by-step method of administering a PARP inhibitor in combination with a PD-1 binding antagonist to a patient in need thereof....
PD-1之后，下⼀个抗癌神药：PARP抑制剂，⾮常有戏对抗癌药PARP抑制剂来说，2011年是⾮常糟糕的⼀年。由于赛诺菲的iniparib在三阴性乳腺 癌的III期临床试验中失败，以及阿斯利康的olaparib在卵巢癌临床试验中受挫，业界⼤⼤降低 了对研发PARP抑制剂的投⼊和兴趣。不过，随着药物研发者们意识到iniparib并不...
[2]PARP1 inhibitor HS-10502, from https://www.cancer.gov/publications/dictionaries/cancer-drug/def/parp1-inhibitor-hs-10502 [3]ClinicalTrials官网. From https://clinicaltrials.gov/study/NCT05740956?term=HS-10502&rank=1 (转自:医药观澜)
参考文献:Chen Z, Wang K, Zhao L and Gong L (2023) BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report. Front. Oncol. 13:1190100. doi: 10.3389/fonc.2023.1190100